Dr. Tadashi Urashima is Performance and Digital Analytics Lead at GSK Japan. In this position, Dr. Urashima is responsible for leading digital transformation in Development and Medical Affairs. Also, Dr. Urashima has over 20 years’ experience in pharmaceutical company and has played roles in clinical development, project management, medical excellence, MSL Manager. Dr. Urashima is in charge of MA community lead and content committee in DIA Japan. He has organized DIA MA forum or DIA MA short course as program chairman. Dr. Urashima holds a PhD in regenerative medicine from Tottori University and has a certification of Associated Certified Coach (ACC) in International Coaching Federation.

Dr. Shinichi Nishiuma is Executive Officer, Chief Medical Officer at Aculys Pharma Inc. After graduating from Kobe University School of Medicine in 1997, he began his medical career as an internist and a gastroenterologist at Kobe City General Hospital. Recognizing issues with the drug lag for hepatitis C treatment, he took on the role of a physician in clinical development at Schering-Plough (now merged into MSD). Following that, he was responsible for clinical development and safety management at Eli Lilly Japan. From 2018, he served as the Head of Medical Division at Celgene Japan (now merged into BMS). In 2022, he became the Chief Medical Officer at Aculys Pharma Inc., where he remains to this day.

Shuji Uno has served as Medical Lead at Medical Affairs department in BMS K.K. since July 2020. Shuji is responsible for Medical Plan development via UMNs identification and any activities of Evidence Generation in hematology area, such as company-sponsored studies, investigator-sponsored studies, and publication. He has over 8 years of experineces in Medical Affairs department including field work experiences as MSL in pharmaceutical industry. He holds a Ph.D. in life science from University of Tokyo.

Hajime “Jim” Saijo, PhD, MBA, is the Sr. VP, managing director of DIA Japan. He previously established and lead the Academia Clinical Research Division, CMIC K.K., as Corporate Officer managing clinical research and investigator sponsored clinical trials. Dr. Saijo’s experience also includes serving as Director of R&D for Alcon Japan; Director of R&D and Representative Director for start-up operations of Ferring Pharmaceuticals Co. Ltd.; and as VP of Medical, Clinical and Regulatory Affairs for Japan & APEC for OvaScience. Dr. Saijo earned his PhD in Medical Science from Tokyo Medical and Dental University Graduate School of Medicine and Dentistry, and his MBA in Business Administration from Temple University Business School, Japan Campus.

Hideki Ninomiya graduated from the University of Tokyo's School of Medicine. After working as a neurosurgeon, he entered the world of data science. He engaged in medical information and telemedicine at Medley Inc. Afterwards, he started his own company, Datack Inc.

Koji Kawakami, MD, PhD is Professor and Chair, Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University. After the residency training in head and neck surgery and otorhinolaryngology, Dr. Kawakami served as postdoc and later promoted to clinical trial (IND) reviewer at CBER of U.S. FDA from 1999-2004. In 2006, Dr. Kawakami moved to Kyoto University to serve his current position, where he conducts various research programs focusing on clinical epidemiology and pharmaco epidemiology, and cost effectiveness researches utilizing various medical and healthcare databases. He has published more than 140 original articles in peer-reviewed global scientific journals as of August 2016.

Takashi is a director of Data Sciences, newly established department, in Janssen Japan R&D Division since June, 2019. His professional experiences range from Discovery Research, Clinical Development to Medical Affairs in Liver, Diabetes, Cardiovascular/Metabolic, Infection, Hematology and others. He also has extensive experiences in Clinical Statistics and IT system/database/sofware development during his 19-years of pharma industry career (Pfizer, RaQualia, Eli Lilly, Gilead and Chugai/Roche) after graduating from Duke University in Chemistry and Toxicology (2000). He holds a Ph.D. degree (2012) in NASH research from Nagoya University's Medical School and an Executive MBA degree (2018) from Keio Business School while he worked full-time.

Dr. Yoshiyuki Sugimoto is the Scientifica Advisor in Medical Affairs at AbbVie Japan. Dr. Sugimoto graduated from Faculty of Pharmaceutical Sciences, the University of Tokyo in 1998 and completed Master's course at Graduate School of Pharmaceutical Science, the University of Tokyo in 2000. Dr. Sugimoto Joined Kyowa Hakko Kogyo Co., Ltd. (current Kyowa Kirin Co., Ltd.) in 2000, and moved to AbbVie Japan in 2016. Dr. Sugimoto has over 20 years’ experience in Pharmaceutical industry including Research, Development and Medical Affairs. Currently Dr. Sugimoto works for Rheumatology Medical Affairs Team and plays a leading role in the strategy of rheumatology field. Dr. Sugimoto obtained PhD degree from Waseda University in 2014.